Opportunity Information: Apply for PAR 18 878
The grant opportunity titled "Late Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)" is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA) that supports large, late-stage clinical studies aimed at improving outcomes for people experiencing age-related cognitive decline and for individuals across the full continuum of Alzheimers disease (AD). The emphasis is on taking interventions that are already promising and moving them into Phase II/III or Phase III testing, meaning applicants are expected to propose trials that are relatively advanced in development and focused on demonstrating efficacy and safety (or confirming benefit) in well-defined patient populations. The FOA explicitly includes both pharmacological approaches (such as drugs or biologics) and non-pharmacological approaches (such as behavioral interventions, lifestyle programs, cognitive training, care delivery models, or other non-drug strategies), as long as they are suitable for rigorous late-stage clinical trial evaluation.
A key feature of this FOA is that it requires an R01 application that includes a clinical trial. In practical terms, this means the project must be structured as a true clinical trial with prospective assignment to an intervention, a defined comparison condition (such as placebo, standard of care, or an alternative intervention), and clearly articulated clinical and/or biomarker outcomes. The target populations span from pre-symptomatic individuals (for example, those at risk or with early biological signs) through people with more advanced symptomatic disease. The intent is to support research that can credibly influence clinical practice and patient care by generating high-quality evidence in real-world-relevant populations across different stages of cognitive impairment and AD progression.
The FOA is categorized as discretionary funding and uses the grant mechanism, specifically the NIH R01 research project grant. The activity category is health, and it is associated with CFDA number 93.866. The opportunity number is PAR-18-878, with an original closing date listed as 2022-01-07 and a creation date of 2018-07-26. The listing does not specify an award ceiling or the expected number of awards in the provided source details, which often means applicants would need to consult the full FOA text and NIH institute guidance for budget expectations, project periods, and institute-specific funding plans.
Eligibility is broad and includes many types of applicants that can carry out complex clinical trials. Eligible applicants include state, county, city or township governments, special district governments, independent school districts, and public housing authorities or Indian housing authorities. Academic institutions are eligible, including public and state-controlled institutions of higher education and private institutions of higher education. Tribal entities are included, such as federally recognized Native American tribal governments, as well as Native American tribal organizations other than federally recognized tribal governments. The FOA also allows nonprofit organizations both with and without 501(c)(3) status (as long as they are not institutions of higher education), for-profit organizations other than small businesses, and small businesses. NIH also highlights additional eligible applicant categories that underscore an interest in inclusion and broad participation, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This wide eligibility aligns with the reality that late-stage AD and cognitive decline trials often benefit from multi-site networks, community engagement, diverse recruitment catchment areas, and specialized clinical research infrastructure.
Overall, this opportunity is geared toward teams ready to run rigorous, later-phase trials that can test whether an intervention meaningfully prevents cognitive decline, slows progression, improves cognition or function, or otherwise benefits patients and families across the AD spectrum. Competitive applications would typically be expected to demonstrate strong scientific rationale and preliminary evidence, a feasible and ethically sound trial design, robust recruitment and retention plans (often with attention to representativeness and inclusion), well-justified endpoints, and clear operational capabilities for conducting high-quality Phase II/III or Phase III clinical research.Apply for PAR 18 878
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Late Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2018-07-26.
- Applicants must submit their applications by 2022-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The opportunity is titled "Late Stage Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)."
Which agency is offering this grant?
This is a National Institutes of Health (NIH) Funding Opportunity Announcement (FOA).
What is the opportunity number for this FOA?
The opportunity number is PAR-18-878.
What type of grant mechanism does this FOA use?
The FOA uses the NIH R01 research project grant mechanism.
Is a clinical trial required?
Yes. The FOA requires an R01 application that includes a clinical trial.
What does "clinical trial required" mean in practical terms for the application?
The project must be structured as a true clinical trial, including prospective assignment to an intervention, a defined comparison condition (for example, placebo, standard of care, or an alternative intervention), and clearly articulated clinical and/or biomarker outcomes.
What stage of clinical research is this FOA focused on?
The emphasis is on large, late-stage clinical studies, specifically Phase II/III or Phase III testing. Applicants are expected to propose trials that are relatively advanced in development and focused on demonstrating efficacy and safety (or confirming benefit) in well-defined patient populations.
What is the overall purpose of this FOA?
The FOA supports late-stage clinical studies aimed at improving outcomes for people experiencing age-related cognitive decline and for individuals across the full continuum of Alzheimers disease (AD), with the intent to generate evidence that can credibly influence clinical practice and patient care.
Which conditions or populations does this FOA target?
The FOA targets age-related cognitive decline and the full continuum of Alzheimers disease (AD), spanning from pre-symptomatic individuals (such as those at risk or with early biological signs) through people with more advanced symptomatic disease.
What kinds of interventions can be tested under this FOA?
The FOA explicitly includes both pharmacological approaches (such as drugs or biologics) and non-pharmacological approaches (such as behavioral interventions, lifestyle programs, cognitive training, care delivery models, or other non-drug strategies), as long as they are appropriate for rigorous late-stage clinical trial evaluation.
Does the FOA require a comparison condition in the study design?
Yes. The FOA describes the need for a defined comparison condition, such as placebo, standard of care, or an alternative intervention.
What types of outcomes are expected in supported trials?
The FOA calls for clearly articulated clinical and/or biomarker outcomes.
What kinds of trial endpoints or goals are implied by the FOA?
The FOA is geared toward trials that can test whether an intervention meaningfully prevents cognitive decline, slows progression, improves cognition or function, or otherwise benefits patients and families across the AD spectrum.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.866.
How is this funding categorized?
The FOA is categorized as discretionary funding and uses the grant mechanism.
What is the activity category for this opportunity?
The activity category is health.
What are the key dates listed for this opportunity?
The creation date is 2018-07-26, and the original closing date listed is 2022-01-07.
Does the provided listing specify an award ceiling?
No. The provided source details do not specify an award ceiling.
Does the provided listing state how many awards are expected?
No. The provided source details do not list an expected number of awards.
If award amounts and number of awards are not listed, where would applicants typically look next?
When these details are not included in a listing, applicants would typically consult the full FOA text and NIH institute guidance for budget expectations, project periods, and institute-specific funding plans.
Who is eligible to apply?
Eligibility is broad and includes government entities, academic institutions, tribal entities, nonprofits, for-profits, small businesses, and additional categories highlighted by NIH, including various serving institutions and community-based organizations, as well as non-U.S. (foreign) organizations.
Are state and local governments eligible applicants?
Yes. Eligible applicants include state, county, city or township governments, special district governments, independent school districts, and public housing authorities or Indian housing authorities.
Are colleges and universities eligible to apply?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are tribal governments and tribal organizations eligible?
Yes. Eligible applicants include federally recognized Native American tribal governments and Native American tribal organizations other than federally recognized tribal governments.
Are nonprofit organizations eligible to apply?
Yes. The FOA allows nonprofit organizations both with and without 501(c)(3) status (as long as they are not institutions of higher education).
Are for-profit organizations eligible?
Yes. The FOA includes for-profit organizations other than small businesses, and it also includes small businesses.
Are small businesses eligible to apply?
Yes. Small businesses are listed among eligible applicants.
Are faith-based or community-based organizations eligible?
Yes. The FOA highlights faith-based or community-based organizations among additional eligible applicant categories.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are included among the additional eligible applicant categories.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA includes non-U.S. entities (foreign organizations).
Does NIH specifically encourage participation from certain institution types?
The FOA notes additional eligible applicant categories that underscore inclusion and broad participation, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and others.
What kinds of teams or capabilities does this FOA appear to be designed for?
This opportunity is geared toward teams ready to run rigorous later-phase trials, often benefiting from multi-site networks, community engagement, diverse recruitment catchment areas, and specialized clinical research infrastructure.
What elements are implied to be important for a competitive application?
Based on the description, competitive applications would typically be expected to demonstrate a strong scientific rationale and preliminary evidence, a feasible and ethically sound trial design, robust recruitment and retention plans (often with attention to representativeness and inclusion), well-justified endpoints, and clear operational capabilities for conducting high-quality Phase II/III or Phase III clinical research.
Browse more opportunities from the same category: Health
Next opportunity: Hurricane sandy project support---mapping and research
Previous opportunity: Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 878
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 878) also looked into and applied for these:
| Funding Opportunity |
|---|
| Expanding Extramural Research Opportunities at the NIH Clinical Center (U01 Clinical Trial Optional) Apply for PAR 18 879 Funding Number: PAR 18 879 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Molecular Atlas of Lung Development Program (LungMAP) Phase 2 - Data Coordinating Center (U24- Clinical Trial Not Allowed) Apply for RFA HL 19 022 Funding Number: RFA HL 19 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Psychosis Intervention Network (EPINET): Data Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA MH 19 151 Funding Number: RFA MH 19 151 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Early Psychosis Intervention Network (EPINET): Practice-Based Research to Improve Treatment Outcomes (R01 Clinical Trial Optional) Apply for RFA MH 19 150 Funding Number: RFA MH 19 150 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Genomic Innovator Award (R35 Clinical Trial Optional) Apply for RFA HG 18 006 Funding Number: RFA HG 18 006 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| HIV Services and Systems Strengthening (HS3) Apply for 72051718RFA00003 Funding Number: 72051718RFA00003 Agency: Dominican Republic USAID-Santo Domingo Category: Health Funding Amount: $19,500,000 |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 18 010 Funding Number: RFA MD 18 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) Apply for RFA MD 18 009 Funding Number: RFA MD 18 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Management of Asthma in Primary Care - Clinical Center (UG3/UH3 - Clinical Trial Required) Apply for RFA HL 19 005 Funding Number: RFA HL 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Management of Asthma in Primary Care - Bioinformatics Center (U24 - Clinical Trial Required - Infrastructure) Apply for RFA HL 19 006 Funding Number: RFA HL 19 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed) Apply for RFA AG 19 010 Funding Number: RFA AG 19 010 Agency: National Institutes of Health Category: Health Funding Amount: $5,250,000 |
| 2019 YSEALI Regional Workshop: Partnership in Health – Community-based Prevention for Non-communicable Diseases and Mental Health Apply for PAS ID 18 003 Funding Number: PAS ID 18 003 Agency: U.S. Mission to Indonesia Category: Health Funding Amount: $250,000 |
| Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed) Apply for PAR 18 889 Funding Number: PAR 18 889 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active Cooperative Agreements (U01 Clinical Trial Not Allowed) Apply for PAR 18 890 Funding Number: PAR 18 890 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Neuroprotection (U01 Clinical Trial Not Allowed) Apply for RFA NS 18 033 Funding Number: RFA NS 18 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Extracellular RNA (exRNA) Communication Research: Improved Isolation and Analysis of exRNA-Carrier Subclasses (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 027 Funding Number: RFA RM 18 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited competition: Data Management and Resource Repository (DMRR) on Extracellular RNA (U54 Clinical Trial Not Allowed) Apply for RFA RM 18 026 Funding Number: RFA RM 18 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Neuroprotection - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA NS 18 034 Funding Number: RFA NS 18 034 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Advancing Extracellular RNA (exRNA) Communication Research: Towards Single Extracellular Vesicle (EV) Sorting, Isolation, and Analysis of Cargo (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 028 Funding Number: RFA RM 18 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMHD Minority Health and Health Disparities Research Training (MHRT) Program (T37) Apply for RFA MD 18 007 Funding Number: RFA MD 18 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 878", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.